The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism
Abstract
BACKGROUND: Low molecular weight heparins (LMWH) have been shown to be effective and safe in preventing venous thromboembolism (VTE), and may also be effective for the initial treatment of VTE. OBJECTIVES: To determine the effect of LMWH compared with unfractionated heparin (UFH) for the initial treatment of VTE. SEARCH STRATEGY: Trials were identified from the Cochrane Peripheral Vascular Diseases Group's Specialised Register, CENTRAL and LILACS. Colleagues and pharmaceutical companies were contacted for additional information. SELECTION CRITERIA: Randomised controlled trials comparing fixed dose subcutaneous LMWH with adjusted dose intravenous or subcutaneous UFH in people with VTE. DATA COLLECTION AND ANALYSIS: At least two reviewers assessed trials for inclusion and quality, and extracted data independently. MAIN RESULTS: Twenty-two studies were included (n = 8867). Thrombotic complications occurred in 151/4181 (3.6%) participants treated with LMWH, compared with 211/3941 (5.4%) participants treated with UFH (odds ratio (OR) 0.68; 95% confidence intervals (CI) 0.55 to 0.84, 18 trials). Thrombus size was reduced in 53% of participants treated with LMWH and 45% treated with UFH (OR 0.69; 95% CI 0.59 to 0.81, 12 trials). Major haemorrhages occurred in 41/3500 (1.2%) participants treated with LMWH, compared with 73/3624 (2.0%) participants treated with UFH (OR 0.57; 95% CI 0.39 to 0.83, 19 trials). In eighteen trials, 187/4193 (4.5%) participants treated with LMWH died, compared with 233/3861 (6.0%) participants treated with UFH (OR 0.76; 95% CI 0.62 to 0.92). Nine studies (n = 4451) examined proximal thrombosis; 2192 participants treated with LMWH and 2259 with UFH. Subgroup analysis showed statistically significant reductions favouring LMWH in thrombotic complications and major haemorrhage. By the end of follow up, 80 (3.6%) participants treated with LMWH had thrombotic complications, compared with 143 (6.3%) treated with UFH (OR 0.57; 95% CI 0.44 to 0.75). Major haemorrhage occurred in 18 (1.0%) participants treated with LMWH, compared with 37 (2.1%) treated with UFH (OR 0.50; 95% CI 0.29 to 0.85). Nine studies (n = 4157) showed a statistically significant reduction favouring LMWH with respect to mortality. By the end of follow up, 3.3% (70/2094) of participants treated with LMWH had died, compared with 5.3% (110/2063) of participants treated with UFH (OR 0.62; 95% CI 0.46 to 0.84). REVIEWERS' CONCLUSIONS: LMWH is more effective than UFH for the initial treatment of VTE. LMWH significantly reduces the occurrence of major haemorrhage during initial treatment and overall mortality at follow up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Self-citationHirsh, J., & Levine, M. (1992) · Blood · doi:10.1182/blood.v79.1.1.bloodjournal7911 · Cited by 894
Oates, J. A., Wood, A. J. J., & Hirsh, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242206 · Cited by 830
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.-P., Azarian, R., Laurent, M., Hirsch, J.-L., Ferrari, E., Bosson, J.-L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371002 · Cited by 782
Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Hull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Trowbridge, A. A., Elliott, C. G., Lerner, R. G., Hall, J., Sparling, T., Brettell, H. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261502 · Cited by 700
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Jaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Saposnik, G., Barinagarrementeria, F., Brown, R. D., Bushnell, C. D., Cucchiara, B., Cushman, M., deVeber, G., Ferro, J. M., & Tsai, F. Y. (2011) · Stroke · doi:10.1161/str.0b013e31820a8364 · Cited by 1,970
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
Thrombosis of the Cerebral Veins and Sinuses
Stam, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra042354 · Cited by 1,587
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Deep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Ferro, J. M., Bousser, M. ‐., Canhão, P., Coutinho, J. M., Crassard, I., Dentali, F., di Minno, M., Maino, A., Martinelli, I., Masuhr, F., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13381 · Cited by 749
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Frontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
Büller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E. M., Cariou, R., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00007 · Cited by 617
Self-citationKyrle, P. A., & Eichinger, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71880-8 · Cited by 616
EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients
Einhäupl, K., Stam, J., Bousser, M. ‐., De Bruijn, S. F. T. M., Ferro, J. M., Martinelli, I., & Masuhr, F. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03011.x · Cited by 528
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., & Schulman, S. (2004) · Chest · doi:10.1378/chest.126.3_suppl.287s · Cited by 515
British Thoracic Society guidelines for the management of suspected acute pulmonary embolism
Campbell, I. A., Fennerty, A., & Miller, A. C. (2005) · PULMONOLOGIYA · doi:10.18093/0869-0189-2005-0-4-19-39 · Cited by 458
Perioperative Management of Patients Receiving Oral Anticoagulants: A Systematic Review
Dunn, A. S., & Turpie, A. G. G. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.8.901 · Cited by 434
Mazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402
“LMWHs are at least as effective as UFH and probably safer.(40) Fondaparinux can also be used as parenteral agent.”
BackgroundDeep-Vein Thrombosis of the Upper Extremities
Kucher, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1008740 · Cited by 373
Superficial Venous Thrombosis and Venous Thromboembolism: A Large, Prospective Epidemiologic Study
Decousus, H., Quéré, I., Presles, E., Becker, F., Barrellier, M.-T., Chanut, M., Gillet, J.-L., Guenneguez, H., Leandri, C., Mismetti, P., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-4-201002160-00006 · Cited by 353
Farge, D., Bounameaux, H., Brenner, B., Cajfinger, F., Debourdeau, P., Khorana, A. A., Pabinger, I., Solymoss, S., Douketis, J., & Kakkar, A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30369-2 · Cited by 347
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Crowther, M. A., & Warkentin, T. E. (2008) · Blood · doi:10.1182/blood-2007-10-120543 · Cited by 314
Erkens, P. M., & Prins, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub3 · Cited by 301
Self-citationEFNS guideline on the treatment of cerebral venous and sinus thrombosis
Einhäupl, K., Bousser, M. ‐., De Bruijn, S. F. T. M., Ferro, J. M., Martinelli, I., Masuhr, F., & Stam, J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01398.x · Cited by 298
Kline, J. A., Nordenholz, K. E., Courtney, D. M., Kabrhel, C., Jones, A. E., Rondina, M. T., Diercks, D. B., Klinger, J. R., & Hernandez, J. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12521 · Cited by 291
BULLER, H., DEITCHMAN, D., PRINS, M., & SEGERS, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03054.x · Cited by 252
Self-citationThe diagnosis and treatment of venous thromboembolism
Wells, P., & Anderson, D. (2013) · Hematology · doi:10.1182/asheducation-2013.1.457 · Cited by 70
Metadata
- Authors
- van Dongen, C. J., van den Belt, A. G., Prins, M. H., & Lensing, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2004-10-18
- Issue
- 4
- Pages
- CD001100-CD001100
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4230743743
- Cited by
- 433
- References
- 41
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.